WONDFO BIOTECH(300482)2024-10-28 09:41Financial Performance - In Q3 2024, the company achieved operating revenue of 606.11 million yuan, a year-on-year increase of 17.51% [1] - Net profit attributable to shareholders reached 80.14 million yuan, up 22.70% from the previous year [1] - Net profit excluding non-recurring gains and losses was 62.70 million yuan, reflecting a significant growth of 49.89% year-on-year [1] Business Segments - The international department maintained stable qualitative business while experiencing rapid growth in quantitative business, particularly in overseas fluorescence platforms [1] - The U.S. subsidiary's toxicology business remained stable, with significant growth expected in respiratory infectious disease testing, including new COVID-19 and flu combination tests [2] - Domestic operations are divided into qualitative and quantitative segments, with qualitative business showing rapid growth in infectious disease testing [2] Market Expansion - The company is actively expanding sales channels, focusing on offline pharmacies, supermarkets, and online platforms like Amazon [2] - Localized factories are being established in various countries to mitigate potential policy risks and enhance market opportunities [3] - The company has successfully registered respiratory combination tests in several countries, anticipating future business opportunities [4] Cost and Profitability - Sales and management expenses increased in Q3 due to the recognition of stock incentive costs, but overall expense ratios have decreased compared to the previous year [3] - Gross margin showed a slight improvement due to product structure optimization and increased sales of higher-margin products [4] Future Outlook - The international department is expected to continue strong performance, with significant growth anticipated in the fourth quarter driven by respiratory disease products [4] - The company remains confident in achieving its annual revenue and profit targets despite external challenges [4]